| PROGRAM/TARGET | INDICATION | DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|---|---|
| ZE63-0302 Menin |
NPM1 AND KMT2A | |||||
| Undisclosed | ||||||
| Undisclosed | ||||||
| Undisclosed | ||||||
| PROGRAM/TARGET | ZE46-0134 FLT3/IRAK4 |
|---|---|
| INDICATION | HEALTHY VOLUNTEER STUDY |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | PAN-FLT3/IRAK4 |
|---|---|
| INDICATION | ZE46-0134 FLT3/IRAK4 |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | PAN-FLT3/IRAK4 |
|---|---|
| INDICATION | SPLICESOSOMES AML/MDS |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | PAN-FLT3/IRAK4 |
|---|---|
| INDICATION | AML FLT3 gatekeeper |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | ZE50-0134 BCL2 |
|---|---|
| INDICATION | CLL VENETOCLAX NAIVE |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | ZE50-0134 BCL2 |
|---|---|
| INDICATION | AML |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | ZE63-0302 MENIN |
|---|---|
| INDICATION | AML (NMP1 AND KMT2AR) |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | UNDISCLOSED |
|---|---|
| INDICATION |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | UNDISCLOSED |
|---|---|
| INDICATION |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| PROGRAM/TARGET | UNDISCLOSED |
|---|---|
| INDICATION |
| DISCOVERY | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|